scholarly journals Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature

2021 ◽  
Vol 8 (2) ◽  
Author(s):  
Mary M Czech ◽  
Ashwin K Nayak ◽  
Kavitha Subramanian ◽  
Jose F Suarez ◽  
Jessica Ferguson ◽  
...  

Abstract Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the treatment of autoimmune rheumatic diseases. We describe a case of Chagas disease reactivation in a woman taking azathioprine and prednisone for limited cutaneous systemic sclerosis (lcSSc). Reactivation manifested as indurated and erythematous cutaneous nodules. Sequencing of a skin biopsy specimen confirmed the diagnosis of Chagas disease. She was treated with benznidazole with clinical improvement in the cutaneous lesions. However, her clinical course was complicated and included disseminated CMV disease and subsequent septic shock due to bacteremia. Our case and review of the literature highlight that screening for Chagas disease should be strongly considered for patients who will undergo immunosuppression for treatment of autoimmune disease if epidemiologically indicated.

2003 ◽  
Vol 36 (4) ◽  
pp. 441-447 ◽  
Author(s):  
Sonia G. Andrade ◽  
Igor Marcelo Oliveira Mesquita ◽  
Jamile F. Jambeiro ◽  
Isis F. Magalhães Santos ◽  
Renata Siqueira Portella

Benznidazole is recommended in Brazil for the treatment of Trypanosoma cruzi infection in acute and early chronic phases of Chagas' disease. Observations by others have indicated a higher incidence of neoplasias in immunosuppressed patients, presenting Chagas' disease reactivation, submitted to treatment with benznidazole. In the present study, we investigated whether there is a potentiation in the generation of lymphomas in chronically infected mice, treated with immunosuppressive drugs and benznidazole. For this, 142 Swiss mice chronically infected with the 21 SF strain of T. cruzi and 72 normal Swiss mice were used. Both infected and normal mice were divided into experimental groups and submitted to one of the following treatment regimens: benznidazole alone; immunosuppressive drugs (azathioprine, betamethasone and cyclosporin); a combination of immunosuppressive drugs and benznidazole; and untreated controls. In the infected group treated with benznidazole, one mouse developed a non-Hodgkin's lymphoma. This finding has been interpreted as a spontaneous tumor of mice. The study of the chronically infected mice treated with the combination of immunosuppressive drugs and benznidazole demonstrated an absence of lymphomas or other neoplasias. These findings support the indication of benznidazole, as the drug of choice, for immunosuppressed patients that develop a reactivation of Chagas' disease.


2020 ◽  
Vol 66 ◽  
pp. 270-276
Author(s):  
Anas Bouzbouz ◽  
Bushra Abdulhakeem ◽  
Rabii Laababsi ◽  
Sami Rouadi ◽  
Reda Abada ◽  
...  

2019 ◽  
Vol 12 (4) ◽  
pp. 189-193 ◽  
Author(s):  
Jonathan T. Kapke ◽  
Robert J. Schneidewend ◽  
Zeeshan A. Jawa ◽  
Chiang-Ching Huang ◽  
Jennifer M. Connelly ◽  
...  

2012 ◽  
Vol 7 (4) ◽  
pp. 179-182 ◽  
Author(s):  
Maria Elena Cavicchiolo ◽  
Paola Berlese ◽  
Silvia Bressan ◽  
Elena Trincia ◽  
Ingrid Inches ◽  
...  

PEDIATRICS ◽  
1973 ◽  
Vol 52 (3) ◽  
pp. 382-387
Author(s):  
Frederick H. Lovejoy ◽  
William E. Boyle

Two cases of linear nevus sebaceous syndrome are described and a review of the eleven cases now reported in the literature is undertaken. The first patient has retardation, seizures, and classic ectodermal lesions while the second patient manifests typical cutaneous lesions and only an elevated cerebrospinal fluid protein as evidence of neurologic disease. The rationale for defining the syndrome as an entity distinct from other neurocutaneous syndromes is discussed and a pleomorphic presentation of the syndrome is suggested.


1993 ◽  
Vol 35 (2) ◽  
pp. 111-116 ◽  
Author(s):  
José Eymard Homem Pittella

A review was made of the available literature on central nervous system (CNS) involvement in Chagas' disease. Thirty-one works concerning the acute nervous form and 17 others dealing with the chronic nervous form, all presenting neuropathologic studies, were critically analysed. Based on this analysis, an attempt was made to establish the possible natural history of CNS involvement in Chagas' disease. Among others, the following facts stand out: 1) the initial, acute phase of Trypanosoma cruzi infection is usually asymptomatic and subclinical; 2) only a small percentage of cases develop encephalitis in the acute phase of Chagas' disease; 3) the symptomatic acute forms accompanied by chagasic encephalitis are grave, with death ensuing in virtually all cases as a result of the brain lesions per se or of acute chagasic myocarditis, this being usually intense and always present; 4) individuals with the asymptomatic acute form and with the mild symptomatic acute form probably have no CNS infection or, in some cases, they may have discrete encephalitis in sparse foci. In the latter case, regression of the lesions may be total, or residual inflammatory nodules of relative insignificance may persist. Thus, no anatomical basis exists that might characterize the existence of a chronic nervous form of Chagas' disease; 5) reactivation of the CNS infection in the chronic form of Chagas' disease is uncommon and occurs only in immunosuppressed patients.


2018 ◽  
Vol 73 ◽  
pp. 322
Author(s):  
M. Fernandez ◽  
S. Besuschio ◽  
D. Nicita ◽  
V. Latini ◽  
M.L. Biondi ◽  
...  

2018 ◽  
Vol 93 (6) ◽  
pp. 890-892 ◽  
Author(s):  
Maria Guillermina Ferraresso ◽  
Ana Clara Torre ◽  
Maria Manuela Martínez Piva ◽  
Laura Barcan

Sign in / Sign up

Export Citation Format

Share Document